A Phase I/II trial to determine the Safety, Toxicity and Efficacy of Iodine-131-Rituximab and the Histone Deacetylase Inhibitor Panobinostat in Relapsed and Refractory Indolent B-cell Lymphoma

Trial Profile

A Phase I/II trial to determine the Safety, Toxicity and Efficacy of Iodine-131-Rituximab and the Histone Deacetylase Inhibitor Panobinostat in Relapsed and Refractory Indolent B-cell Lymphoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2016

At a glance

  • Drugs Panobinostat (Primary) ; Anti-CD20 monoclonal antibody C2B8-I-131; Rituximab
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Acronyms BCELLI
  • Most Recent Events

    • 08 Jun 2016 Status changed from recruiting to completed.
    • 25 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top